Keros Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	244.06	3.55	0.15	-	20.1
Revenue Growth (YoY)	6774.96%	2250.99%	-	-	-
Gross Profit	244.06	3.55	0.15	-	20.1
Selling, General & Admin	46.85	40.75	34.83	27.53	21.33
Research & Development	129.64	173.63	135.26	87.27	55.14
Total Operating Expenses	176.49	214.38	170.09	114.79	76.47
Operating Income	67.57	-210.83	-169.94	-114.79	-56.37
Interest Income	24.87	23.5	14.76	3.64	0.03
Interest Expense	-	-	-	-0	-0
Other Non-Operating Income (Expense)	-0.54	0.28	2.19	6.47	-0.38
Total Non-Operating Income (Expense)	24.33	23.78	16.95	10.11	-0.36
Pretax Income	91.9	-187.05	-152.99	-104.68	-56.73
Provision for Income Taxes	-4.88	-0.3	-	-	-2.01
Net Income	87.01	-187.35	-152.99	-104.68	-58.74
Net Income to Common	87.01	-187.35	-152.99	-104.68	-58.74
Shares Outstanding (Basic)	37	37	29	25	23
Shares Outstanding (Diluted)	38	37	29	25	23
Shares Change (YoY)	1.13%	27.13%	16.66%	8.17%	50.48%
EPS (Basic)	2.34	-5.00	-5.20	-4.15	-2.52
EPS (Diluted)	2.30	-5.00	-5.20	-4.15	-2.52
Free Cash Flow	105.95	-162.8	-126.97	-71.3	-63.17
Free Cash Flow Per Share	2.80	-4.35	-4.31	-2.82	-2.71
Gross Margin	100.00%	100.00%	100.00%	-	100.00%
Operating Margin	27.69%	-5938.96%	-112543.71%	-	-280.46%
Profit Margin	35.65%	-5277.55%	-101319.21%	-	-292.26%
FCF Margin	43.41%	-4585.92%	-84087.42%	-	-314.29%
EBITDA	69.08	-209.6	-169.13	-114.12	-56
EBITDA Margin	28.30%	-5904.34%	-112003.97%	-	-278.58%
EBIT	67.57	-210.83	-169.94	-114.79	-56.37
EBIT Margin	27.69%	-5938.96%	-112543.71%	-	-280.46%
Effective Tax Rate	-5.31%	0.16%	0.00%	0.00%	3.54%

Updated Mar 4, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q